HIV INFECTION

This study tested four different HIV vaccine combinations in 92 healthy volunteers at low risk of HIV. The goal was to see which combination is safest and best at triggering the body's immune system to fight HIV. The vaccines use a 'prime-boost' approach, where the first shot pri…

This study tested whether a double-dose hepatitis B vaccine (40 micrograms) works better than the standard dose (20 micrograms) in people with HIV who had not responded to previous hepatitis B vaccines. The trial included 178 participants and measured how many developed protectiv…

This study looked at how the HIV medication raltegravir works in people with HIV who also have end-stage liver disease and need a liver transplant. Researchers wanted to see how the drug interacts with anti-rejection medicines given after transplant. 14 participants were followed…

This study tested whether people with HIV whose virus is already well-controlled on a three-drug pill (BIC/FTC/TAF) could safely switch to a new two-drug pill (DOR/ISL) taken once daily. Over 600 participants were followed for 48 weeks. The goal was to see if the simpler pill kep…

This study tested a new combination of three HIV medicines (dolutegravir, emtricitabine, and tenofovir alafenamide) in 53 children aged 28 days to 10 years in Africa. The goal was to find the right dose that keeps drug levels high enough to control HIV while being safe. Results w…

This study tested whether the HPV vaccine can reduce high-grade cervical lesions (precancerous changes) in 536 women living with HIV. Participants received either the HPV vaccine or a placebo, and researchers tracked new lesions over one to two years. The goal was to see if the v…

This study tested whether reducing the daily dose of the HIV drug darunavir from 800 mg to 400 mg could keep the virus suppressed in 100 adults who already had undetectable viral loads. Participants were on a stable regimen including darunavir and two other drugs. The goal was to…

This study looked at whether switching to a new once-daily pill (doravirine/islatravir) is safe and effective for people with HIV whose virus is already suppressed by their current medication. Over 600 adults took part. The main goal was to see if the new pill kept the virus unde…

This study tested whether giving two lab-made antibodies (VRC01LS and 10-1074) could keep HIV suppressed in 30 children in Botswana who started HIV treatment very early. The children stopped their regular HIV pills and received antibody infusions instead. The goal was to see if t…

This study tested whether adding the drug maraviroc to standard HIV treatment for 24 weeks could improve immune function in people whose CD4 counts stayed low even though their HIV was well-controlled. The trial included 60 HIV-positive adults with CD4 counts below 350 and little…

This study looked at whether removing small, early-stage anal cancers with local surgery alone is safe and effective for people with HIV. The goal was to see if this less invasive approach could avoid the need for radiation or chemotherapy. Sixteen participants were followed for …

This study tested a 12-week course of telaprevir added to a longer course of peginterferon and ribavirin in 70 adults with both HIV and hepatitis C who had not been helped by earlier treatment. The goal was to see if this combination could clear the hepatitis C virus for good. Th…

This study looked at whether low-dose CT scans can find lung cancer early in people with HIV who have a history of heavy smoking. About 450 participants aged 40 and older received a CT scan to check for lung cancer. The goal was to see how common lung cancer is in this group and …

This early-stage study tested a new lab-made antibody called CAP256J3LS in 24 healthy adults to see if it is safe. The antibody is designed to stop HIV from infecting cells. Participants received either one or three doses by injection or IV, and were monitored for side effects an…

This study tested a program where men who have sex with men in four African countries received HIV prevention care every three months. The care included checkups, STI testing, counseling, and condoms. The goal was to see if this approach could reduce HIV infections in this group …

This study tested whether a personal helper (a systems navigator) could help heterosexual men in Malawi stay on HIV prevention medication (PrEP). The study included 199 men who were getting care for sexually transmitted infections. The navigator provided support and reminders to …

This large study in South Africa tested whether offering HIV treatment right away to everyone who tests positive, instead of waiting until their immune system weakens, can lower the number of new HIV infections in entire communities. Over 28,000 people from 22 villages took part.…

This study tested whether a 12-week high-intensity exercise program could slow aging and reduce inflammation in HIV-positive veterans aged 50 and older. Participants did circuit training combining resistance and aerobic exercises, available via video conferencing. The goal was to…

This study examined 30 HIV-positive adults who had been on effective antiretroviral therapy for at least a year and had undetectable virus levels in their blood. Researchers took gut tissue samples to look for hidden HIV and understand why the virus persists in the body. The goal…

This study looked at whether a lab-made antibody called VRC01 could help people with HIV control the virus without taking daily HIV medication. Thirteen people who got HIV during a vaccine study and had been on HIV drugs for at least a year stopped their medication under close mo…

This study followed 163 children who started HIV treatment very early in life (within 12 weeks of birth) for about seven years. Researchers measured their growth, immune health, and virus levels to understand long-term outcomes. No new treatments were given—the goal was to gather…

This study looked at 167 men who have sex with men and are on HIV treatment with undetectable virus in their blood. Researchers checked if the virus could still be found in their semen. The goal was to understand any remaining risk of passing HIV to a partner, even when blood lev…

This study followed 516 HIV-positive men who have sex with men to learn how anal HPV infection changes over time and how it might lead to anal cancer. Researchers used exams and special scopes to check for abnormal cells. The goal was to gather information that could help prevent…

This study looked at whether a small genetic change in the TLR7 gene is more common in women with HIV than in healthy women. The goal was to understand if this change affects the body's early immune response to the virus. Researchers studied 90 women, all of whom had HIV and were…

This study looked at how well the kidneys work in 30 people with HIV, comparing those on different medications to healthy volunteers. Researchers used a special water test to find early, hidden kidney problems. The goal was to understand if HIV or its treatments cause subtle kidn…

This study looked at 629 adults with different types of pulmonary arterial hypertension (PAH), including those linked to HIV, heart defects, and connective tissue diseases. Researchers tested blood for antibodies that attack blood vessel and lung cells to see if these immune mark…